Abstract
Cluster of differentiation 36 (CD36) links lipid handling to ligand-induced signaling in diabetic kidney disease (DKD), but its contribution to injury varies with cell type and metabolic conditions. This narrative review evaluates the evidence connecting CD36 to redox injury by comparing experimental interventions, functional measurements, and rescue studies. In podocytes, RNA turnover and palmitoylation regulate receptor availability. Tubular studies link CD36 manipulation to oxidative metabolism, mitochondrial oxidant signaling, and inflammatory amplification of lipid peroxidation. Alternative uptake routes, discordant localization findings, and lipid accumulation without a full fibrotic phenotype argue against a uniformly harmful role for CD36. We propose a model in which receptor availability affects ligand handling and signaling, while intracellular lipid processing and peroxide defense shape susceptibility to injury. Evaluation of receptor-directed interventions should account for the cell and protein-substrate selectivity of trafficking regulators. Human studies identify candidate CD36 measurements for evaluation in defined diagnostic, prognostic and treatment-response settings. Combining cell-specific receptor perturbation and appropriate reconstitution controls with substrate tracing and defined redox measurements provides a framework for testing renal protection after diabetic injury has developed.